drugset / Trial / NCT01954238

A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers

NCT01954238

Phase 1 Completed 46 enrolled Green Cross Corporation Parexel · collab
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and Pharmacokinetics/Pharmacodynamics of multiple doses of GCC-4401C in healthy male subjects.

Timeline

Start
2013-08
Primary completion
2014-03
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator GCC-4401C Small molecule 10 mg Oral
Comparator GCC-4401C Small molecule 20 mg Oral
Comparator GCC-4401C Small molecule 40 mg Oral
Comparator GCC-4401C Small molecule 60 mg Oral
Comparator GCC-4401C Small molecule 80 mg Oral
Subject Rivaroxaban Other / unclassified 20 mg Oral

Indications

No indication recorded.